Highlights

  • Immutep discontinued its TACTI-004 Phase III lung cancer study after an interim futility assessment in March 2026.
  • The company reported manufacturing differences identified during its continuing TACTI-004 root cause investigation.
  • Its revised efti development focus covers selected head and neck cancer patients and neoadjuvant soft tissue sarcoma.
  • July 2026 INSIGHT-003 data reported median overall survival of 30.9 months in 51 evaluable patients.
  • Immutep continues development of its separate LAG-3 agonist programme, IMP761, for autoimmune diseases.

Immutep Limited (ASX:IMM) is a clinical-stage biotechnology company developing LAG-3-related immunotherapies for cancer and autoimmune diseases, according to its corporate website. Its 2026 clinical programme has undergone a significant reassessment after the discontinuation of a late-stage lung cancer trial, alongside a narrower development strategy for eftilagimod alfa (efti) and continuing work on its autoimmune pipeline.

TACTI-004 Outcome Reshapes the Lung Cancer Programme

In March 2026, an independent data monitoring committee recommended that the TACTI-004 Phase III study in first-line non-small cell lung cancer be discontinued after a planned interim futility analysis. The recommendation followed a review of available efficacy and safety data. Immutep Limited (ASX:IMM) halted enrolment and began an orderly study wind-down, including patient follow-up and trial-site closure.

A futility finding means the study was unlikely to achieve its intended efficacy objective under the assessment criteria; it does not establish that every earlier result was invalid. The outcome nevertheless changed the company’s near-term clinical priorities and prompted a review of clinical, pharmacological and manufacturing factors.

Manufacturing Review and Revised Efti Priorities

On 11 September 2026, Immutep Limited (ASX:IMM) reported that its investigation had found subtle analytical and structural differences between efti manufactured at 200 L and 2,000 L scales, including a difference in N-glycan structure. The company described those findings as potentially relevant to the different immune-activation patterns observed in TACTI-004. The root cause investigation had not been completed, so a definitive explanation was not established.

The company contracted a new 200 L manufacturing run. Its intended registration-directed efti development now centres on head and neck squamous cell carcinoma in patients with negative PD-L1 expression (CPS below 1), and neoadjuvant treatment of soft tissue sarcoma. Immutep Limited (ASX:IMM) indicated that future study starts were targeted for the second half of 2027, dependent on trial design, regulators, manufacturing, partners and resources.

Clinical Evidence and Broader Pipeline

In July 2026, the company reported mature median overall survival of 30.9 months from the investigator-initiated INSIGHT-003 Phase I study involving 51 evaluable patients with non-squamous non-small cell lung cancer. These findings come from a separate study and should not be presented as overturning the TACTI-004 futility outcome.

Immutep Limited (ASX:IMM) also develops IMP761, an agonist antibody targeting LAG-3 for autoimmune diseases. Its April 2026 US orphan drug designation for efti in soft tissue sarcoma and previously obtained fast-track designation for head and neck cancer relate to regulatory development pathways, not product marketing approval.

Funding and Development Considerations

Immutep received approximately A$0.86 million through an R&D tax incentive announced on 30 September 2026. Development expenditure, manufacturing consistency, regulatory discussions and recruitment into future trials remain relevant operational considerations. Immutep Limited (ASX:IMM) must also manage the uncertainty inherent in clinical testing: results from smaller studies do not guarantee success in later, larger trials.

Key Insights

Immutep’s 2026 disclosures describe a material change in its lead cancer programme, rather than uninterrupted clinical progression. The TACTI-004 discontinuation, the incomplete manufacturing investigation and the concentration on selected oncology settings define its current development position. The separate INSIGHT-003 evidence and IMP761 programme provide additional clinical context, although neither removes the development and regulatory uncertainties facing Immutep Limited (ASX:IMM).